Catalyst Pharmaceutical Partners, Inc. Announces Initiation Of An Expanded Access Program To Provide Firdapse At No Cost To U.S. Patients With Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla.--(BUSINESS WIRE)--Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the United States its investigational potassium channel inhibitor, Firdapse™ (amifampridine phosphate or 3,4-DAP phosphate), to patients diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS) through their neuromuscular disease specialists. The product, currently in Phase 3 development, will be provided at no cost until sometime after approval. Program enrollment will begin in the next few months, pending FDA review and approvals.
Help employers find you! Check out all the jobs and post your resume.